Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2018

Basis of Accounting, Policy [Policy Text Block]

	(a)	Basis of Preparation

		The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of March 31, 2018 and for the three months ended March 31, 2018 and 2017 are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly our financial position as of March 31, 2018, results of operations for the three months ended March 31, 2018 and 2017, and cash flows for the three months ended March 31, 2018 and 2017. The results for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018 or for any other interim period or for any other future year.

		These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10 -K for the year ended December 31, 2017, filed with the SEC on March 16, 2018.

Going Concern and Liquidity [Policy Text Block]

	(b)	Liquidity

		We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of $76.0 million as of March 31, 2018. Management expects operating losses and negative cash flows to continue through the next several years. Based on management’s current plans, management believes cash and cash equivalents of $9.7 million as of March 31, 2018 are sufficient to fund the Company into the fourth quarter of 2018. These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

		Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP cell therapy system, and our second therapeutic candidate, the CardiALLO cell therapy system, through and beyond the fourth quarter of 2018, will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be no assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.

Use of Estimates, Policy [Policy Text Block]

(c)

Use of Estimates

The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation.

Consolidation, Policy [Policy Text Block]

(d)

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process.

Revenue from Contract with Customer [Policy Text Block]

(e)

Changes to

Significant Accounting Policies

Our significant accounting policies are described in Note

of the notes to the financial statements included in our Annual Report on Form

-K filed for the year ended

2017.

Apart from the adoption of ASU

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

) on

January 1, 2018

which led to an amended revenue policy, as described in the following paragraphs, there have been

changes to those policies.

Revenue Recognition

Net product revenue

– We currently have a portfolio of enabling and delivery products. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred.

Collaboration agreement revenue

– Collaboration agreement revenue is income from agreements under partnering programs with corporate and academic institutions, wherein we provide biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. These programs provide additional clinical data, intellectual property rights and opportunities to participate in the development of combination products for the treatment of cardiac disease.

Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.

Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.

New Accounting Pronouncements, Policy [Policy Text Block]

(

)

Recently Adopted Accounting Pronouncement

May 2014,

the FASB issued Topic

606,

which provides comprehensive guidance for revenue recognition. Topic

606

affects any entity which either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. The core principle of the guidance provides that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings.

January

2018,

we adopted Topic

606

using the cumulative effect adoption method. Results for reporting periods beginning after

January

2018

are presented under Topic

606

, while prior period amounts are

not

adjusted and continue to be reported in accordance with our historic accounting under Topic

605.

The adoption of Topic

606

did

not

have a material impact on our financial statements.

January 2016,

the FASB issued ASU

No.

2016

(ASU

2016

), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU

2016

changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the update clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. We adopted ASU

2016

January 1, 2018

and the adoption did

not

have a material impact on our financial statements.

May 2017,

the FASB issued ASU

No.

2017

Compensation – Stock Compensation (Topic

718

) Scope of Modification Accounting (ASU

2017

). The amendments in ASU

2017

provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic

718.

We adopted ASU

2017

effective

January 1, 2018,

and the adoption did

not

have a material impact on our financial statements.

(

)

Recently Issued Accounting Pronouncements

February 2016,

the FASB issued ASU

No.

2016

Leases (Topic

842

) (ASU

2016

), which supersedes existing guidance on accounting for leases in Leases (Topic

840

) and generally requires all leases to be recognized in the consolidated balance sheet. ASU

2016

is effective for annual and interim reporting periods beginning after

December 15, 2018;

early adoption is permitted. The Company does

not

plan to elect early adoption. The provisions of ASU

2016

are to be applied using a modified retrospective approach. The Company is currently assessing the future impact of this ASU on its consolidated financial statements.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did

not

or are

not

believed by management to have a material impact on the Company’s financial statement presentation or disclosures.